5 Things That Marijuana Stock GW Pharmaceuticals plc's Management Wants You To Know

Few areas have been as intriguing to investors this year as medical marijuana. The approval of legislation allowing its use in states such as Colorado has kicked off a flurry of commentary regarding the good and bad of marijuana use. That increased interest has flowed over to drugmakers that are developing medicine based on the cannibinoids found inside marijuana, including GW Pharmaceuticals .

I previously discussed three hurdles that GW Pharma may need to overcome, but today let's study what its management is saying for clues that might help investors value this emerging biotech company.

 

Source: GW Pharmaceuticals.

1. Advancing Epidiolex
"We anticipate a launch date for the initial Dravet syndrome trial in late September, early October with the second Dravet and the two Lennox-Gastaut trials to follow in early 2015," said CEO Justin Glover during the company's

...
Rate this article: 

This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.


URL: 
http://www.nasdaq.com/article/5-things-that-marijuana-stock-gw-pharmaceuticals-plcs-management-wants-you-to-know-cm385165#ixzz3BliJEx6S